Last reviewed · How we verify
Placebo to neostigmine
Placebo to neostigmine is a Cholinesterase inhibitor Small molecule drug developed by Merck Sharp & Dohme LLC. It is currently in Phase 3 development for Myasthenia gravis, Postoperative ileus or urinary retention.
Neostigmine is a cholinesterase inhibitor that increases acetylcholine levels by blocking the enzyme acetylcholinesterase, enhancing neuromuscular transmission.
Neostigmine is a cholinesterase inhibitor that increases acetylcholine levels by blocking the enzyme acetylcholinesterase, enhancing neuromuscular transmission. Used for Myasthenia gravis, Postoperative ileus or urinary retention.
At a glance
| Generic name | Placebo to neostigmine |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Cholinesterase inhibitor |
| Target | Acetylcholinesterase |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Neostigmine reversibly inhibits acetylcholinesterase, preventing the breakdown of acetylcholine at the neuromuscular junction and in the central nervous system. This leads to increased acetylcholine accumulation, which enhances cholinergic signaling and improves muscle strength and parasympathetic function. The drug is used to treat conditions characterized by impaired neuromuscular transmission or cholinergic deficiency.
Approved indications
- Myasthenia gravis
- Postoperative ileus or urinary retention
Common side effects
- Muscle fasciculations
- Increased salivation
- Bronchospasm
- Bradycardia
- Nausea and vomiting
- Diarrhea
Key clinical trials
- Sugammadex as Rescue Therapy (PHASE4)
- To Observe Haemodynamic Parameters Including, Heart Rate, Blood Pressure, Respiratory Rate , and Oxygen Saturation, With or Without Giving Reversal Agent on Extubation, in Patients Receiving Single Shot of Atracurium , and to Observe Post Operative Residual Paralysis and Airway Reflexes in PACU. (PHASE1, PHASE2)
- Comparative Study Between Dexmedetomidine & Neostigmine as an Adjuvant to Local Anesthetic Mixture in Peribulbar Block in Vitreoretinal Surgeries (EARLY_PHASE1)
- Redesigned Process in the Operating Room (PHASE2, PHASE3)
- Use of a Prokinetic Agent as an Adjunct to Thrice Weekly Bowel Care After SCI (PHASE1)
- Different Doses of Neostigmine for Reversal of Moderate Neuromuscular Blockade in Children (PHASE4)
- Reversal of Neuromuscular Blockade With Sugammadex or Usual Care in Hip Fracture Surgery or Joint (Hip/Knee) Replacement (P07038) (PHASE3)
- Duloxetine Potentiates the Analgesic Efficacy of Intrathecal Morphine (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to neostigmine CI brief — competitive landscape report
- Placebo to neostigmine updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI
Frequently asked questions about Placebo to neostigmine
What is Placebo to neostigmine?
How does Placebo to neostigmine work?
What is Placebo to neostigmine used for?
Who makes Placebo to neostigmine?
What drug class is Placebo to neostigmine in?
What development phase is Placebo to neostigmine in?
What are the side effects of Placebo to neostigmine?
What does Placebo to neostigmine target?
Related
- Drug class: All Cholinesterase inhibitor drugs
- Target: All drugs targeting Acetylcholinesterase
- Manufacturer: Merck Sharp & Dohme LLC — full pipeline
- Therapeutic area: All drugs in Neurology
- Indication: Drugs for Myasthenia gravis
- Indication: Drugs for Postoperative ileus or urinary retention
- Compare: Placebo to neostigmine vs similar drugs
- Pricing: Placebo to neostigmine cost, discount & access